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Mortality in adult patients with culture-positive and 
culture-negative meningitis in the Botswana national 
meningitis survey: a prevalent cohort study
Mark W Tenforde, Margaret Mokomane, Tshepo B Leeme, Nametso Tlhako, Katlego Tsholo, Tony Chebani, Anya Stephenson, Jemima Hutton, 
Hannah K Mitchell, Raju KK Patel, William J Hurt, Tlhagiso Pilatwe, Tiny Masupe, Mooketsi Molefi, Brandon L Guthrie, Carey Farquhar, 
Madisa Mine, Joseph N Jarvis 
Summary
Background CNS infections are a leading cause of HIV-related deaths in sub-Saharan Africa, but causes and outcomes 
are poorly defined. We aimed to determine mortality and predictors of mortality in adults evaluated for meningitis in 
Botswana, which has an estimated 23% HIV prevalence among adults. 
Methods In this prevalent cohort study, patient records from 2004–15 were sampled from the Botswana national 
meningitis survey, a nationwide audit of all cerebrospinal fluid (CSF) laboratory records from patients receiving a 
lumbar puncture for evaluation of meningitis. Data from all patients with culture-confirmed pneumococcal and 
tuberculous meningitis, and all patients with culture-negative meningitis with CSF white cell count (WCC) above 
20 cells per µL were included in our analyses, in addition to a random selection of patients with culture-negative CSF 
and CSF WCC of up to 20 cells per µL. We used patient national identification numbers to link CSF laboratory 
records from the national meningitis survey to patient vital registry and HIV databases. Univariable and multivariable 
Cox proportional hazards models were used to evaluate clinical and laboratory predictors of mortality. 
Findings We included data from 238 patients with culture-confirmed pneumococcal meningitis, 48 with culture-
confirmed tuberculous meningitis, and 2900 with culture-negative CSF (including 1691 with CSF WCC of up to 
20 cells per µL and 1209 with CSF WCC above 20 cells per µL). Median age was 37 years (IQR 31–46), 
1605 (50%) of 3184 patients were male, 2188 (72%) of 3023 patients with registry linkage had documentation of HIV 
infection, and median CD4 count was 139 cells per µL (IQR 63–271). 10-week and 1-year mortality was 47% (112 of 238) 
and 49% (117 of 238) for pneumococcal meningitis, 46% (22 of 48) and 56% (27 of 48) for tuberculous meningitis, 
and 41% (1181 of 2900) and 49% (1408 of 2900) for culture-negative patients. When the analysis of patients with 
culture-negative CSF was restricted to those with known HIV infection, WCC (0–20 cells per µL vs >20 cells per µL) 
was not predictive of mortality (average hazard ratio 0·93, 95% CI 0·80–1·09). 
Interpretation Mortality from pneumococcal, tuberculous, and culture-negative meningitis was high in this setting of 
high HIV prevalence. There is an urgent need for improved access to diagnostics, to better define aetiologies and 
develop novel diagnostic tools and treatment algorithms.
Funding National Institutes of Health, President’s Emergency Plan for AIDS Relief, National Institute for Health 
Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
CNS infections are a leading cause of mortality in 
sub-Saharan Africa.1,2 The emergence of HIV markedly 
altered the epidemiology of meningitis in the region; 
cryptococcal meningitis, tuberculous meningitis, and 
bacterial meningitis caused by Streptococcus pneumoniae are 
the most common confirmed causes in adults in central, 
east, and, southern Africa.3–5 Outcomes from cryptococcal 
meningitis have been relatively well described in clinical 
trials and observational studies.6–9 However, data regarding 
long-term outcomes from tuberculous or pneumococcal 
meningitis in routine-care settings are limited.5,10,11
Furthermore, most patients with suspected meningitis 
evaluated by lumbar puncture and cerebrospinal fluid 
(CSF) analysis in resource-limited settings have no 
pathogen identified through diagnostic studies.3,4 Even in 
studies that have used enhanced molecular diagnostics, 
up to half of patients still did not have a definitive micro-
biological diagnosis.12–14 The aetiology of CNS infections 
therefore remains poorly understood, manage ment 
recommendations for this large patient population are 
lacking, and no data exist on short-term or long-term 
survival.
Botswana, which has an estimated HIV prevalence of 
23% among adults, has an electronic national death 
registry unique within the region, as well as an 
electronic national HIV registry used for research and 
surveillance.15 We aimed to determine long-term 
Lancet Infect Dis 2019; 
19: 740–49
See Comment page 676
Division of Allergy and 
Infectious Diseases, 
Department of Medicine, 
University of Washington 
School of Medicine, Seattle, 
WA, USA (M W Tenforde MD, 
Prof C Farquhar MD); 
Department of Epidemiology, 
University of Washington 
School of Public Health, 
Seattle, WA USA 
(M W Tenforde, B L Guthrie PhD, 
Prof C Farquhar); 
Botswana-UPenn Partnership, 
Gaborone, Botswana 
(M W Tenforde, T B Leeme MBBS, 
N Tlhako DipN, K Tsholo DipN, 
A Stephenson MBChB, 
J Hutton MBBS, 
H K Mitchell BMBS, 
R KK Patel MBBS, 
W J Hurt BMchB, 
Prof J N Jarvis MD); Botswana 
National Health Laboratory, 
Gaborone, Botswana 
(M Mokomane MSc, 
M Mine PhD); Botswana 
Ministry of Health, Gaborone, 
Botswana (T Chebani MSc, 
T Pilatwe MSc); Department of 
Family Medicine and Public 
Health, University of 
Botswana, Gaborone, 
Botswana (T Masupe MD, 
M Molefi MBChB); Department 
of Global Health, University of 
Washington, Seattle, WA USA 
(B L Guthrie, Prof C Farquhar) 
Division of Infectious Diseases, 
Department of Medicine, 
Perelman School of Medicine, 
University of Pennsylvania, 
Philadelphia, PA, USA 
(Prof J N Jarvis); Botswana 
Harvard AIDS Institute 
Partnership, Gaborone, 
Botswana (Prof J N Jarvis); and 
Department of Clinical 
Research, Faculty of Infectious 
and Tropical Diseases, London 
School of Hygiene and Tropical 
Medicine, London, UK 
(Prof J N Jarvis)
Articles
www.thelancet.com/infection   Vol 19   July 2019 741
Correspondence to: 
Mark Tenforde, Division of 
Allergy and Infectious Diseases, 
Department of Medicine, 
University of Washington School 
of Medicine, Seattle, 
WA 98195, USA  
mark.tenforde@gmail.com
See Online for appendix
For more on Botswana HIV and 
AIDS estimates see http://www.
unaids.org/en/regionscountries/
countries/Botswana
mortality and predictors of mortality in adults evaluated 
for meningitis in Botswana.
Methods
Study design and participants
In this retrospective prevalent cohort study, we 
compared outcomes for patients with culture-confirmed 
tuberculous or pneumococcal meningitis, culture-
negative meningitis with abnormal CSF cellular 
findings, and culture-negative cases with a relatively 
normal CSF profile, and evaluated clinical and lab-
oratory predictors of mortality up to 1 year. 
Patient records from Jan 1, 2004, to Dec 31, 2015, were 
sampled from the Botswana national meningitis survey, 
a nationwide audit of all CSF laboratory records from 
patients receiving a lumbar puncture for evaluation of 
suspected meningitis.16
The Botswana national meningitis survey included 
both paper CSF records and electronic records from a 
national electronic medical record, the Integrated Patient 
Management System (IPMS). IPMS was rolled out in 
Botswana’s public hospital laboratory system in 2004, 
and by 2014 covered over 72% of patients undergoing 
CSF analysis (appendix). Paper and electronic data were 
merged, de-duplicated, and stored in an online database 
(REDCap).
Standard CSF work-up included glucose concentration, 
protein concentration, and white cell count (WCC) with 
or without neutrophil and lymphocyte percentages in 
those patients with elevated WCC. Microbiological 
testing included Gram stain, India ink stain, and 
standard bacterial and fungal cultures on all samples. 
Cryptococcal antigen (CrAg) latex agglutination testing 
was available in some laboratories. Tuberculosis culture 
was done at the request of clinical providers at a central 
national tuberculosis reference laboratory. The Xpert 
MTB/RIF assay for tuberculosis was introduced in 
Botswana in August, 2012, but not used on CSF samples. 
Details of the standard diagnostic work-up for CSF and 
meningitis treatment regimens in Botswana are listed in 
the appendix.
Cases of suspected meningitis were defined as culture-
negative if no pathogen was identified on standard 
microbiological testing—ie, they had a negative bacterial 
culture and Gram stain, negative work-up for cryptococcal 
meningitis (including microscopy, CrAg testing, and 
fungal culture), and any tuberculosis microscopy or 
cultures were negative. For assessment of culture-
negative meningitis outcomes the dataset was restricted 
to patients with a nine-digit national identification 
number (known as Omang) in IPMS—a unique 
identification number assigned to all Botswana citizens 
Research in context
Evidence before this study
CNS infections are a leading cause of HIV-related deaths globally. 
In regions of high HIV prevalence in sub-Saharan Africa, 
cryptococcal, tuberculous, and pneumococcal meningitis are the 
most common confirmed aetiologies of meningitis; cryptococcal 
meningitis alone causes 15% of all HIV deaths. Although 
cryptococcal meningitis is easily confirmed with widely available 
and sensitive diagnostic tests and culture is frequently used, 
additional diagnostic studies are infrequently available. In 
settings of high HIV prevalence, most individuals who receive a 
lumbar puncture with cerebrospinal fluid (CSF) analysis for 
evaluation of infection have no aetiology identified. We searched 
PubMed, EMBASE, and PubMed Central for studies published 
between Jan 1, 1990, and Aug 31, 2018, of short-term and 
long-term outcomes of culture-positive and culture-negative 
meningitis in routine clinical care settings of sub-Saharan Africa. 
Search terms included regional search terms for sub-Saharan 
Africa and meningitis. In-hospital mortality for culture-negative, 
lymphocyte-predominant meningitis in two small studies of 
mostly HIV-infected patients was 13% in one study, and 35% in 
the other. Our search yielded no published studies describing 
long-term outcomes of patients evaluated for meningitis 
without a pathogen identified in settings of high HIV prevalence.
Added value of this study
We assessed mortality in patients in Botswana with 
culture-confirmed tuberculous and pneumococcal meningitis 
and patients with culture-negative meningitis with CSF white 
cell count (WCC) elevation (>20 cells per µL), as well as a 
random sample of culture-negative cases with minimal 
(WCC 0–2 cells per µL) or mild (WCC 3–20 cells per µL) 
inflammatory changes. Almost three-quarters of patients had 
known HIV infection, a majority with advanced disease 
(CD4 count <200 cells per µL), and half of patients without a 
confirmed pathogen died within 1 year. In the context of 
advanced HIV infection, CSF WCC was not a predictor of 
mortality, and tuberculous meningitis was rarely confirmed by 
culture. To our knowledge, this is the only large study in 
sub-Saharan Africa to provide robust estimates of short-term 
and long-term outcomes of both culture-positive and 
culture-negative meningitis in routine clinical care settings. 
Implications of all the available evidence
Our findings highlight an exceedingly high mortality among 
HIV-infected patients evaluated for CNS infection in Botswana, 
and a poor ability of health-care providers to discriminate who 
is most at risk of death through available information such as 
CSF WCC. These findings support an urgent need to scale up 
existing diagnostics, particularly available molecular diagnostics 
for tuberculosis, and highlight a need to prioritise research in 
development and evaluation of sensitive, affordable, and rapid 
diagnostic tests to inform better management strategies and 
reduce mortality.
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who are at least 16 years of age. Omang is recorded when 
patients are registered in IPMS at the time of first hospital 
admission, and the identification number is verified at 
each subsequent admission.
All patient records with CSF WCC above 20 cells per µL 
were selected for analysis, plus a random selection of 
1000 CSF samples with negative cultures and normal CSF 
WCC (0–2 cells per µL) and 1000 CSF samples with mildly 
abnormal CSF WCC (3–20 cells per µL). We selected 
1000 random samples within both of the CSF WCC strata 
for pragmatic reasons, based on a data agreement with the 
Botswana Ministry of Labour and Home Affairs which 
maintains the death registry. Samples were randomly 
selected on the basis of a random number sequence 
generated with Stata (version 13.0, College Station, TX, 
USA). WCC categories were used because mild 
pleocytosis, typically below 20 cells per µL, is common in 
asymptomatic HIV-infected adults, and for consistency 
with previously published data.4 Repeat samples from the 
same patient were excluded, as were patients subsequently 
found to have positive microscopy in the absence of 
positive cultures. Children usually do not have an assigned 
Omang; therefore, selection of culture-negative patients 
was restricted to individuals who were at least 16 years 
of age.
The national identification number was used for 
deterministic linkage of patient CSF laboratory data to 
HIV-related data in the national HIV registry. 
Antiretroviral therapy (ART) was available in Botswana 
starting in 2002, and HIV prevalence in adults 
(15–49 years) remained stable (from 25% in 2004 to 23% 
in 2015). We obtained records of HIV status from the HIV 
registry; for HIV-positive patients we obtained records of 
their most recent CD4 counts within 6 months of lumbar 
puncture and on whether the patient had initiated ART 
before lumbar puncture evaluation.17 The date of ART 
initiation was defined either as ART documented in the 
registry before the date of lumbar puncture, or in the 
absence of documented ART initiation, 90 days before the 
date of first recorded HIV viral load result. This definition 
was chosen because ART prescription might be 
incompletely documented and baseline viral load testing 
is not done in Botswana but recommended 3 months 
post-ART initiation.17 All-cause mortality within 1 year 
following initial lumbar puncture was assessed through 
deterministic linkage by unique identification number to 
the national electronic death registry. From this registry, a 
previous study6 captured vital status for up to 1 year for 
93% of patients treated for cryptococcal meningitis at a 
Botswana referral hospital from 2012–14, suggesting 
high-quality capture. In 2014, an estimated 89% of deaths 
were registered within 1 month.18
1-year mortality was also assessed for all cases of 
culture-confirmed S pneumoniae meningitis in IPMS (S 
pneumoniae accounted for most cases of culture-
confirmed bacterial meningitis) and all cases of culture-
confirmed tuberculous meningitis from 2007 onward. 
Records of culture-confirmed tuberculous meningitis are 
stored in Disa, Botswana’s National Tuberculosis 
Reference Laboratory’s electronic medical record; IPMS 
does not store tuberculosis culture results.  The records 
were linked to the death registry by Omang (when 
available) or by first name and surname, and by Omang 
only to the HIV registry.
The study was approved by institutional review boards at 
the University of Pennsylvania (Philadelphia, PA, USA), 
Culture-confirmed bacterial meningitis No pathogen identified 
Pneumococcal meningitis 
(n=238)
Tuberculous meningitis 
(n=48)
CSF white cell count 
0–20 cells per µL (n=1691)
CSF white cell count above 
20 cells per µL (n=1209)
Age (years) 32·6 (17·7–42·3) 34·1 (23·8–45·2) 37·8 (31·2–46·8) 37·0 (30·9–44·7)
Sex
Female 141 (59%) 24 (50%) 868 (51%) 548 (45%)
Male 97 (41%) 24 (46%) 823 (49%) 661 (55%)
Unknown .. 2 (4%) .. ..
CSF white cell count (cells per µL)* 236 (53–800) 65 (25–185) 2 (2–5) 115 (50–325)
Lymphocytes (%) 10% (5–25) 93% (32–97) 90% (70–98) 88% (42–95)
Protein (g/dL) 4·14 (2·5–7·1) 3·13 (2·6–3·5) 0·55 (0·30–1·07) 1·89 (1·03–3·42)
Glucose (mmol/L) 0·04 (0·01–0·12) 2·73 (1·99–3·48) 3·22 (2·57–3·83) 1·85 (1·07–2·84)
HIV positive 79 (64%) 22 (76%) 1211 (72%) 898 (74%)
If HIV positive
CD4 T-cell count (cells per µL) 221 (141–421) 105 (34–162) 133 (51–265) 141 (73–270)
On antiretroviral therapy 35 (44%) ·· 605 (50%) 390 (43%)
2-week mortality (%) 44·1% (105) 37·5% (18) 28·6% (484) 29·4% (355)
10-week mortality (%) 47·1% (112) 45·8% (22) 40·1% (678) 41·6% (503)
1-year mortality (%) 49·2% (117) 56·3% (27) 48·4% (819) 48·7% (589)
Data are median (IQR) or n (%), or % (n). CSF=cerebrospinal fluid. *The upper limit recorded for white cell count was 2000 cells per µL. 
Table 1: Baseline clinical and laboratory characteristics and mortality outcomes
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University of Washington (Seattle, WA, USA), and 
University of Botswana (Gaborone, Botswana), and by the 
Health Research and Development Committee of the 
Botswana Ministry of Health (Gaborone, Botswana). As 
the study involved only retrospective collection of routine 
clinical and outcomes data, a waiver of informed patient 
consent was obtained.
Outcomes
The main study outcomes included 10-week and 1-year 
mortality for pneumococcal, tuberculous, and culture-
negative meningitis, and clinical and laboratory predictors 
of mortality.
Statistical analysis
Demographic, clinical, and laboratory characteristics 
were described with summary statistics. The χ² and 
Wilcoxon rank sum tests were used to compare 
categorical and continuous characteristics between 
groups. Kaplan-Meier survival curves were generated for 
tuberculous meningitis and pneumococcal meningitis 
cases, and for culture-negative cases.
Univariable Cox proportional hazards models were 
constructed with 10-week and 1-year mortality data from 
first lumbar puncture as the outcome, to evaluate 
characteristics associated with short-term and long-term 
mortality. Because patients without known HIV in this 
dataset are likely to represent a mix of HIV-uninfected 
individuals and HIV-infected but undiagnosed individuals, 
an analysis restricted to HIV-infected patients was done. 
Variables were dichotomised with clinically meaningful or 
previously established cutoffs:4,6,8 older age (≥50 years), 
elevated CSF WCC (>20 cells per µL), lymphocyte-
predominant CSF (≥50%), low CSF glucose concentration 
(<1 mmol/L), high CSF protein concentration (≥1 g/dL), 
and facility type (referral hospital vs primary or district 
hospital). CD4 cell counts were stratified as above 350 cells 
per µL, 200–350 cells per µL, 100–200 cells per µL, 
Figure 1: Sampling method for selection of patients with culture-positive and culture-negative CSF
IPMS=Integrated Patient Management System. WCC=white cell count.
19 409 CSF records in IPMS 2004–15
16 495 records of culture-negative CSF samples
4629 excluded
 4370 age below 16 years
 259 no age data
11 866 records in patients at least 16 years old
10 056 records with national identification number
2900 records of culture-negative CSF samples
 included in analysis
2914 records of culture-positive CSF samples
 2400 Cryptococcus spp
 245 Streptococcus pneumoniae
 76 Haemophilus influenzae
 48 Mycobacterium tuberculosis
 2 Neisseria meningitidis
 152 other
293 records in patients with pneumococcal or 
 tuberculous meningitis
286 records of culture-positive CSF samples
 included in analysis
7 excluded as repeat isolates
1000 randomly selected
 records of CSF samples
 with WCCs of 
 0–2 cells per μL
112 excluded
 49 repeat
 isolates
 63 positive 
 microscopy
888 records included in 
 this analysis
1000 randomly selected
 records of CSF samples 
 with WCCs of 
 3–20 cells per μL
197 excluded
 104 repeat
    isolates
    93 positive 
    microscopy
803 records included in 
 this analysis
1702 records of CSF 
 samples with WCCs
 greater than 
 20 cells per μL
493 excluded
 298 repeat
     isolates
 195 positive 
     microscopy
1209 records included in 
 this analysis
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50–100 cells per µL, and up to 50 cells per µL. We also 
assessed hazards of death by calendar year to assess 
temporal trends.
Multivariable Cox proportional hazards models were 
constructed with older age, sex, CSF WCC above 20 cells 
per µL, CD4 strata, ART status, facility level, and calendar 
year as independent variables. Variables were selected a 
priori because of suspected causal association with 
mortality to evaluate independent predictors of death. A 
subgroup analysis restricted to HIV-infected patients with 
CSF WCC above 20 cells per µL was done to evaluate 
additional associations between CSF profiles (lymphocyte 
predominance vs neutrophil predominance) and mortality. 
CSF chemistries (protein and glucose concentrations) and 
HIV viral loads were excluded from multivariable models 
because of high degree of missingness, and in the case of 
viral load, a high likelihood that data were not missing at 
random. Because of the fewer cases of culture-confirmed 
pneumococcal meningitis, only univariable regression 
analyses were done and restricted to 10-week mortality, 
because most deaths occurred within the first 10 weeks 
after lumbar puncture. Univariable models estimated 
mortality hazard ratios per 100 cells per µL difference in 
WCC, 1 g/L difference in CSF protein concentration, and 
1 mmol/L difference in CSF glucose concentration. 
p values were obtained with conventional standard errors 
(significance level p≤0·05). Statistical analyses were done 
in Stata (version 13·0, College Station, TX, USA).
Role of the funding source
The funders for this study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of this report, or decision to submit this paper for 
publication. MWT had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
The Botswana national meningitis survey included 29 704 
CSF records from 2004–15, representing 27 432 unique 
cases after repeat CSF samples from a single admission 
were excluded. Among all CSF records from 2004–15, 
21 941 (80%) of 27 432 had no pathogen identified and 
5491 (20%) had one or more pathogens identified. 
Cryptococcal meningitis accounted for 4532 (82%) of 
5491 microbiological diagnoses, tuberculous meningitis 
for 63 (1%), and pneumococcal or other bacterial 
meningitis for 977 (18%), with 45 (1%) having multiple 
diagnoses. 
19 409 (65%) of the 29 704 CSF records included in the 
Botswana national meningitis survey were in IPMS and 
sampled for this analysis. We included data from 
3186 patients in our analysis: 238 with culture-
confirmed pneumococcal meningitis, 48 with culture-
confirmed tuberculous meningitis, and 2900 with 
culture-negative CSF (including 1691 with CSF WCC of 
up to 20 cells per µL and 1209 with CSF WCC greater 
than 20 cells per µL; table 1). Although India ink and 
fungal cultures are routinely done, CrAg testing was 
done on only 703 (4%) of 19 409 samples registered on 
IPMS during the study period. Tuberculous meningitis 
testing was rare, with culture done on 1723 (9%) of 
19 409 samples and AFB microscopy on 2524 (13%). 
Tuberculosis cultures were obtained from Disa; 39 of 
those 48 patients also had a record in the IPMS. The 
cohorts of patients with culture-positive or culture-
negative meningitis are described in figure 1. Overall, 
the median age of patients sampled in the study was 37 
years (IQR 31–46); 1605 (50%) of 3184 patients were 
male, 2188 (72%) of 3023 patients with registry linkage 
had documentation of HIV infection, and median CD4 
count was 139 cells per µL (IQR 63–271). 2345 (74%) of 
3186 patients were treated at one of two national referral 
hospitals. For patients with culture-negative meningitis, 
2109 (73%) of 2900 had documented HIV infection. 
CD4 cell count was measured within 6 months of 
lumbar puncture in 1578 (75%) of these 2109 
HIV-positive individuals, with a median 136 cells per µL 
(IQR 61–266). 956 (45%) of 2109 patients with known 
HIV were on ART by the date of lumbar puncture; 615 
(64%) of these 956 had a documented ART start date in 
IPMS, and 341 (36%) were classified as being on ART 
based on previous viral load testing. Compared with the 
1691 patients with low CSF WCC (≤20 cells per µL), the 
1209 patients with elevated CSF WCC (>20 cells per µL) 
were more likely to be male (661 [55%] patients with 
elevated CSF WCC vs 823 [49%] patients with low CSF 
WCC; p=0·001) and less likely to be on ART before 
lumbar puncture (390 [43%] patients with elevated CSF 
WCC vs 605 [50%] patients with low CSF WCC; 
p=0·003), but had a marginally higher median CD4 
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Pneumococcal
Tuberculous
Culture-negative
Cryptococcal
238
48
2900
236
127
26
1753
115
126
24
1627
96
125
22
1578
90
124
22
1545
86
123
22
1519
80
121
21
1493
76
Time (days)
0 60
0
Su
rv
iv
al
 (%
)
25
50
75
100
120 180 240 300 360
Pneumococcal
Tuberculous
Culture-negative
Cryptococcal
Figure 2: Kaplan-Meier survival analysis of patients with pneumococcal meningitis, tuberculous meningitis, 
culture-negative meningitis, and cryptococcal meningitis
Dashed vertical lines represent 2 weeks, 10 weeks, and 1 year. Cryptococcal meningitis data are previously 
published 2012–2014 referral hospital outcomes for comparison.6
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count (median 141 cells per µL [IQR 73–270] in patients 
with elevated CSF WCC vs 133 cells per µL in patients 
with low CSF WCC [51–265]; p=0·010). Previous known 
HIV status did not differ significantly between CSF 
WCC strata (898 [74%] in patients with elevated CSF 
WCC vs 1221 [72%] in patients with low CSF WCC; 
p=0·11).
999 (83%) of 1209 patients with culture-negative CSF 
and elevated CSF WCC (WCC >20 cells per µL) had 
differential cell counts; 734 (73%) of 999 had 
lymphocyte-predominant CSF. Only 78 of 1691 patients 
with low CSF WCC (≤20 cells per µL) had differential 
counts; 64 (82%) of 78 had lymphocyte-predominant 
CSF. CSF protein concentration was higher and glucose 
concentration lower in patients with CSF WCC above 
20 cells per µL, compared with those who had CSF 
WCC of up to 20 cells per µL (all p<0·0001).
Kaplan-Meier survival curves are shown in figure 2 for 
patients with pneumococcal meningitis, tuberculous 
meningitis, and culture-negative meningitis, as well as 
previously published 2012–14 referral hospital outcomes 
from cryptococcal meningitis for comparison.6 For culture-
confirmed pneumococcal meningitis, 2-week mortality 
was 44% (105 of 238), 10-week mortality was 47% (112 of 238), 
and 1-year mortality was 49% (117 of 238; table 1). 
105 (90%) of those 117 deaths occurred within 2 weeks of 
CSF evaluation. For culture-confirmed tuberculous 
meningitis, 2-week mortality was 38% (18 of 48), 10-week 
mortality was 46% (22 of 48), and 1-year mortality 
56% (27 of 48). For culture-negative patients, overall 2-week 
mortality was 29% (839 of 2900), 10-week mortality was 
41% (1181 of 2900), and 1-year mortality was 
49% (1408 of 2900). There was no significant difference in 
risk of mortality between WCC strata (p>0·05 for 2-week, 
10-week, and 1-year mortality; figure 3). In both the 
pneumococcal meningitis cohort and the culture-negative 
cohort, mortality was higher in patients without known 
HIV diagnosis. 44 (36%) of 123 patients with culture-
confirmed pneumococcal meningitis and HIV registry 
linkage had unknown HIV status; for those patients, 
2-week mortality was 77% (34 of 44), 10-week mortality was 
82% (36 of 44), and 1-year mortality was 82% (36 of 44). 791 
(27%) of 2900 patients with culture-negative CSF and HIV 
registry linkage had unknown HIV status; for those 
patients, 2-week mortality was 43% (344 of 791), 10-week 
mortality was 55% (438 of 791), and 1-year mortality was 
62% (487 of 791).
For patients with culture-confirmed pneumococcal 
meningitis, univariable analysis showed that increased 
CSF WCC was associated with lower risk of mortality 
within 10 weeks of lumbar puncture (hazard ratio 
[HR] 0·96, 95% CI 0·92–0·99 for each increase in WCC 
of 100 cells per µL); when the analysis was restricted to 
those with known HIV infection, increased WCC was 
also associated with lower risk of mortality (HR 0·93, 
95% CI 0·87–0·99 for each increase in WCC of 100 cells 
per µL; appendix). However, higher CSF protein 
concentration in these patients was associated with 
higher risk of mortality (HR 1·04, 95% CI 1·00–1·09 for 
1 g/L increase in protein; appendix).
Univariable analysis in HIV-infected patients with 
negative cultures showed that older age, male sex, low 
CSF glucose concentration, lower CD4 cell count, and 
treatment at non-tertiary facilities were significantly 
associated with increased risk of mortality within 1 year 
(table 2). Calendar year was not associated with risk of 
death (data not shown). Adjusting for other covariates in 
multivariable analyses, older age and lower CD4 cell 
count were associated with higher risk of mortality, and 
baseline ART use with lower risk of mortality (table 3).
Figure 3: Kaplan-Meier analysis of survival for patients with culture-negative meningitis
(A) Probability of survival of patients with CSF WCC 0–2 cells per µL, CSF WCC 3–20 cells per µL, and CSF WCC above 
20 cells per µL. (B) Probability of survival of patients with CSF WCC above 20 cells per µL by neutrophil versus 
lymphocyte (≥50% lymphocytes) predominance. Dashed vertical lines represent 2 weeks, 10 weeks, and 1 year. 
Note that a proportion of patients with WCC above 20 cells per µL did not have a WCC differential. 
CSF=cerebrospinal fluid. WCC=white cell count.
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In an adjusted analysis restricted to HIV-infected 
patients with clear evidence of CSF inflammation (WCC 
>20 cells per µL), lymphocyte-predominant CSF was 
associated with lower mortality at 10 weeks and 1 year 
after lumbar puncture (appendix). Mortality at 2 weeks, 
10 weeks, and 1 year was 42% (110 of 265), 55% (145 of 
265), and 61% (162 of 265) for patients with neutrophil 
predominance and CSF WCC above 20 cells per µL; and 
24% (179 of 734), 36% (261 of 734), and 43% (314 of 734) 
for patients with lymphocyte predominance. Older age 
and lower CD4 cell count were associated with a 
significantly increased risk of death within 10 weeks and 
1 year of lumbar puncture, and ART use at the time of 
lumbar puncture with lower risk of death (appendix).
Discussion
In this routine-care setting with high HIV prevalence in 
sub-Saharan Africa, almost half of the 3186 patients we 
evaluated for CNS infection died within 1 year of lumbar 
puncture. These figures represent conservative mortality 
estimates, as a small proportion of deaths in Botswana 
probably go unregistered.18 Three-quarters of patients had 
known HIV infection with a median CD4 count below 
150 cells per µL; however, the high mortality seen in these 
patients cannot be attributed to advanced HIV infection 
alone. For comparison, in 2002–13 the estimated 1-year 
mortality in patients (with a median baseline CD4 count of 
147 cells per µL) newly accessing ART in the Botswana 
ART programme was 4·3%.15 Mortality was high in both 
culture-confirmed tuberculous and pneumococcal 
meningitis, with very rapid mortality in patients with 
pneumococcal meningitis. Our data showed similarly high 
mortality in patients with culture-negative meningitis, 
without a pathogen identified through available 
microbiological studies. Mortality did not differ in patients 
with clear evidence of CSF inflammation and in those with 
relatively normal CSF cell count, although neutrophil-
predominant CSF predicted poor outcome in patients with 
pleocytosis. To our knowledge, with data from over 
3000 unique patients, this is the first large study to describe 
long-term mortality of patients evaluated for CNS 
infections in a setting of high HIV prevalence.
Diagnosis of CNS infections is challenging in 
sub-Saharan Africa, owing to limited laboratory and 
N (%) 10-week mortality 1-year mortality
n/N (%) HR (95% CI) p value n/N (%) HR (95% CI) p value
Age (n=2109)
Below 50 years 1830 (87%) 598/1830 (33%) 1 (ref) p<0·0001 752/1830 (41%) 1 (ref) p<0·0001
At least 50 years 279 (13%) 145/279 (52%) 1·80 (1·50–2·16) ·· 169/279 (61%) 1·75 (1·48–2·06) ··
Sex (n=2109)
Female 1069 (51%) 345/1069 (32%) 1 (ref) p=0·0059 425/1069 (40%) 1 (ref) p=0·0006
Male 1040 (49%) 398/1040 (38%) 1·22 (1·06–1·41) ·· 496/1040 (48%) 1·26 (1·10–1·43) ··
WCC category (n=2109)
0–20 cells per µL 1211 (57%) 431/1211 (36%) 1 (ref) p=0·53 539/1211 (45%) 1 (ref) p=0·306
Above 20 cells per µL 898 (43%) 312/898 (35%) 0·95 (0·83–1·10) ·· 382/898 (43%) 0·93 (0·82–1·06) ··
CSF protein concentration (n=673)
Below 1 g/L 350 (52%) 102/350 (29%) 1 (ref) p=0·0078 136/350 (39%) 1 (ref) p=0·026
At least 1 g/L 323 (48%) 126/323 (39%) 1·43 (1·10–1·85) ·· 151/323 (47%) 1·30 (1·03–1·64) ··
CSF glucose concentration (n=1031)
At least 1 mmol/L 907 (88%) 318/907 (35%) 1 (ref) p=0·051 394/907 (43%) 1 (ref) p=0·013
Below 1 mmol/L 124 (12%) 55/124 (44%) 1·33 (1·00–1·77) ·· 69/124 (56%) 1·38 (1·07–1·78) ··
CD4 strata (n=1578)
Above 350 cells per µL 261 (17%) 54/261 (21%) 1 (ref) p<0·0001 73/261 (28%) 1 (ref) p<0·0001 
200–350 cells per µL 299 (19%) 87/299 (29%) 1·48 (1·05–2·07) ·· 112/299 (38%) 1·43 (1·07–1·92) ··
100–200 cells per µL 388 (25%) 131/388 (34%) 1·76 (1·28–2·42) ·· 173/388 (45%) 1·78 (1·35–2·33) ··
50–100 cells per µL 310 (20%) 144/310 (46%) 2·61 (1·91–3·57) ·· 175/310 (56%) 2·52 (1·92–3·31) ··
At least 50 cells per µL 320 (20%) 159/320 (50%) 2·82 (2·07–3·84) ·· 189/320 (59%) 2·67 (2·04–3·50) ··
ART status (n=2109)
Off ART 1114 (53%) 409/1114 (37%) 1 (ref) p=0·18 498/1114 (45%) 1 (ref) p=0·32
On ART 995 (47%) 334/995 (34%) 0·91 (0·78–1·05) ·· 423/995 (43%) 0·94 (0·82–1·07) ··
Facility type (n=2109)
Primary or district hospital 582 (28%) 235/582 (40%) 1 (ref) p=0·0017 287/582 (49%) 1 (ref) p=0·0007
Referral hospital 1527 (72%) 508/1527 (33%) 0·78 (0·67–0·91) ·· 634/1527 (42%) 0·79 (0·68–0·90) ··
CSF=cerebrospinal fluid. HR=hazard ratio
Table 2: Univariable analysis of mortality in HIV-infected patients without a pathogen identified 
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imaging infrastructure and the effect of HIV infection on 
CSF findings.4 A substantial majority of individuals with 
meningitis in routine-care settings in Botswana had a 
negative diagnostic evaluation, similar to previous studies 
from other countries in sub-Saharan Africa with high HIV 
prevalence.3,4 Undiagnosed cryptococcal meningitis may 
have accounted for some cases of culture-negative 
meningitis. CrAg testing was infrequently done and the 
highly sensitive IMMY lateral flow assay (Norman, OK, 
USA) was not used in Botswana during the study period;19 
however, standard evaluation with combination India ink 
microscopy and fungal culture is likely to detect most 
cases. Bacterial meningitis cases may be under-diagnosed 
with conventional culture-based methods; preliminary 
findings from a molecular diagnostics study at Botswana’s 
largest referral hospital showed that six (38%) of 
16 patients with pneumococcal meningitis were diagnosed 
by PCR alone, with negative culture results (Jarvis JN, 
unpublished). Cases may represent undiagnosed 
tuberculosis, other serious opportunistic infections, or 
viral pathogens that require molecular diagnostics for 
confirmation; our findings of extremely high mortality 
within 1 year of evaluation strongly suggest severe 
underlying pathology in many patients, requiring 
improved diagnostics to enable effective treatment.
Undiagnosed tuberculous meningitis may have 
contributed to the high mortality in culture-negative 
cases, even in those patients with relatively normal CSF 
cell count. Compared with HIV-uninfected patients with 
tuberculous meningitis, patients with advanced HIV 
are more likely to have atypical CSF findings 
including neutrophil predominance or relatively acellular 
CSF.20 Culture-confirmed tuberculous meningitis was 
uncommon in Botswana compared with previous studies 
in South Africa, where CSF testing for tuberculous 
meningitis is more common.4,5 In 2017, estimated overall 
tuberculosis incidence was 300 cases per 100 000 person-
years in Botswana and 567 cases per 100 000 person-years 
in South Africa.21 Xpert MTB/RIF, endorsed by WHO for 
the diagnosis of tuberculous meningitis,22 has limited 
sensitivity and was not used in Botswana during the 
study period, and tuberculosis culture has a suboptimal 
sensitivity of around 50–60%.23 Second-generation Xpert 
MTB/RIF (Ultra) has improved sensitivity over culture 
and first-generation Xpert MTB/RIF in HIV-infected 
patients,24 making this an attractive diagnostic option. 
Our findings strongly suggest a need for an enhanced 
diagnostic approach in settings with high HIV prevalence 
and tuberculosis burden, including evaluation for 
tuberculous meningitis for all cases of suspected 
meningitis without another clear underlying aetiology. 
Evidence of tuberculosis elsewhere in the body, coupled 
with CSF and imaging findings, may also suggest 
probable tuberculous meningitis and guide treatment.23
Molecular diagnostic studies in African health settings 
suggest that HIV-associated CNS infections due to 
treatable infections, including herpes viruses and 
Toxoplasma gondii, are common and under-diagnosed in 
routine care when enhanced diagnostics are not 
available.12–14 Development and scale-up of sensitive and 
affordable multiplex assays for meningitis may assist in 
guiding therapy and improving outcomes. Further detailed 
studies to define underlying aetiologies are needed to 
inform how best to develop and deploy such diagnostics.
We found significantly higher mortality in patients 
evaluated for meningitis without known HIV infection, 
almost certainly reflecting a survival bias in which 
patients with undiagnosed advanced HIV were dying 
shortly after hospital presentation, before a HIV diagnosis 
could be established. Although almost three-quarters of 
patients evaluated for meningitis without a pathogen 
identified and 64% of those with pneumococcal 
meningitis were known to be HIV-infected, these figures 
likely underestimate true HIV prevalence. For example, 
HIV prevalence in previous studies in Malawi and 
South Africa was at least 90% in patients with bacterial 
meningitis.4,25 In our study, CD4 cell count was an 
important predictor of mortality in patients with known 
HIV infection, similar to previous analyses.26 ART use 
before evaluation was also associated with improved 
survival, likely from a combination of improved outcomes 
for certain CNS infections (eg, progressive multifocal 
leukoencephalopathy) and decreased risk death from 
other HIV-related co-infections or malignancies. In 
10-week mortality 1-year mortality 
aHR (95% CI) p value aHR (95% CI) p value
Age
<50 years 1 (ref) p<0·0001 1 (ref) p<0·0001
≥50 years 1·74 (1·41–2·14) ·· 1·65 (1·36–2·00) ··
Sex
Female 1 (ref) p=0·73 1 (ref) p=0·68
Male 1·02 (0·87–1·22) ·· 1·03 (0·89–1·20) ··
WCC category
0–20 cells per µL 1 (ref) p=0·68 1 (ref) p=0·38
Above 20 cells per µL 0·96 (0·81–1·14) ·· 0·93 (0·80–1·09) ··
CD4 strata
>350 cells per µL 1 (ref) p<0·0001 1 (ref) p<0·0001
200–350 cells per µL 1·51 (1·08–2·13) ·· 1·47 (1·10–1·98) ··
100–200 cells per µL 1·80 (1·31–2·48) ·· 1·83 (1·39–2·42) ··
50–100 cells per µL 2·56 (1·87–3·52) ·· 2·50 (1·90–3·30) ··
≤50 cells per µL 2·85 (2·08–3·90) ·· 2·71 (2·06–3·57) ··
ART status
Off ART 1 (ref) p<0·0001 1 (ref) p<0·0001
On ART 0·70 (0·59–0·83) ·· 0·74 (0·64–0·87) ··
Facility type
Primary or district hospital 1 (ref) p=0·062 1 (ref) p=0·068
Referral hospital 0·84 (0·70–1·01) ·· 0·86 (0·73–1·01) ··
Analyses were adjusted for age, sex, WCC category, CD4 strata, ART status, year, and facility level. aHR=average hazard 
ratio. WCC=white cell count. ART=antiretroviral therapy. 
Table 3: Multivariable analysis of mortality in HIV-infected patients without a pathogen identified 
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patients with confirmed pneumococcal meningitis, we 
found that lower CSF leucocyte counts were significantly 
associated with higher mortality, as has been previously 
described in HIV-associated cryptococcal and tuberculous 
meningitis.8,27 Our findings suggest that absence of a 
robust immune response might be an important predictor 
of mortality in HIV-related bacterial meningitis, in part, 
explaining why clinical trials have not shown a mortality 
benefit with adjunctive glucocorticoid therapy in HIV-
infected patients.25
Neutrophil-predominant meningitis was associated 
with higher mortality than lymphocyte-predominant 
meningitis. This could be in part attributable to bacterial 
meningitis being common among these neutrophil-
predominant culture-negatives cases, with negative 
culture results caused by previous antibiotic exposure, 
lumbar puncture delays, or inadequate culture methods. 
However, overall mortality in patients with lymphocytic 
meningitis was still high at 36% at 10 weeks and 43% at 
1 year. This study improves our understanding of 
outcomes of culture-negative lymphocytic meningitis. 
One small study in the Central African Republic28 found 
a 13% (6/46) in-hospital mortality for HIV-infected 
patients admitted with lymphocytic meningitis (defined 
as CSF WCC >5 cells per µL, >50% mononuclear cells, 
and negative bacterial and fungal microscopy and 
culture), whereas a study from Zimbabwe11 found a 
35% (15/43) in-hospital mortality for HIV-infected 
patients with lymphocytic meningitis (defined as CSF 
WCC >100 cells per µL with >50% mononuclear cells). 
Our findings highlight how lymphocytic meningitis 
cannot be discounted as a benign viral or other self-
limited process in settings of high HIV prevalence.
Our study has several limitations. First, detailed 
information on patients’ clinical presentation, evaluations 
including imaging studies, and clinical management 
including prior antimicrobial use were not available. 
Second, HIV-related data were derived from an electronic 
registry that is incomplete, particularly with respect to 
ART status and history including treatment default.15 
Third, there was substantial missingness of data for 
some variables and likely non-random missingness 
(eg, for HIV viral load), which precluded a multiple 
imputation approach to missing data and inclusion of 
certain variables in adjusted regression models. Fourth, 
we restricted our analysis to a sample of adults in the 
electronic medical record with available national 
identification numbers, potentially missing a small 
proportion of non-citizens and over-representing patients 
receiving care at referral centres. We believe that our 
sampling method resulted in conservative mortality 
estimates compared with the full cohort of adults 
receiving evaluation for meningitis, as non-citizens are 
likely to have worse access to HIV and other health 
services, and patients cared for at referral centres had 
lower mortality than patients at primary or district 
hospitals in Botswana. Fifth, in any prevalent cohort 
study the possibility of lead-time bias exists. However, 
most patients with meningitis present to health facilities 
for diagnostic evaluation rapidly on becoming acutely 
symptomatic, thus lead-time bias is unlikely to occur. 
Finally, it was necessary to make certain assumptions 
that might have led to misclassification of a small 
number of patients (eg, in determining ART start date). 
We also assumed that all patients received a lumbar 
puncture for suspected CNS infection. This assumption 
is supported by data from a prospective cohort study at 
Botswana’s main referral hospital where lumbar 
punctures done between January, 2017, and June, 2018, 
were almost exclusively for evaluation of suspected CNS 
infection rather than for evaluation of cancer, 
autoimmune disorders, or other non-infectious work-up 
(Jarvis JN, unpublished).
In summary, we found very high mortality for cases of 
pneumococcal and tuberculous meningitis, indicating 
the need for earlier diagnosis and better therapies for 
patients treated in HIV-prevalent, resource-limited 
settings. The large majority of meningitis cases were in 
patients with culture-negative CSF and unconfirmed 
diagnoses, and these patients had a similarly high 
mortality up to 1 year, suggesting serious undiagnosed 
pathology. Our ability to stratify mortality risk by CSF 
characteristics alone (particularly by CSF WCC) was 
limited, and our findings highlight an urgent need for 
improved access to diagnostics (eg, Xpert and multiplex 
PCR assays) to better define aetiologies and develop 
novel diagnostic tools and treatment algorithms.
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